Scientists Identify Hidden Brain Pathway Behind GLP-1 Weight-Loss Effects

A University of Virginia-led, NIH-funded mouse study found oral GLP-1 drugs may work through a brain reward circuit, not just appetite suppression.

The drugs orforglipron and danuglipron activated the central amygdala and lowered dopamine release during hedonic feeding.

This suggests oral GLP-1 medicines may reduce pleasure-driven eating by dampening the brain’s reward response.

The finding could help explain broader effects of GLP-1 drugs and guide future treatments for addiction-related conditions.